搜索
Ocugen Inc
OCGN添加自选
1.510USD
+0.030+2.03%
收盘 07/02, 13:00（美东）报价延迟15分钟
510.86M总市值
亏损市盈率 TTM
关键数据
1.510今开
1.600最高
6.96M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.06%换手率
1.480昨收
1.495最低
7.35M成交额
亏损市盈率静
88.00市净率
0.00%股息率 TTM
-118.11%ROA
2.72552周最高
0.61量比
-54.05M净利润
338.32M总股本
-0.2320每股收益TTM
2.23Beta
-660.00%ROE
0.80052周最低
7.09%振幅
100.00%毛利率
510.86M总市值
1.73回报/风险
4.65%风险率
TradingKey Ocugen Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Ocugen Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名116/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.43。中期看，股价处于下降通道。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ocugen Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Ocugen Inc亮点
亮点风险
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
业绩增长期
公司处于发展阶段，最新年度总收入4.41M美元
估值低估
公司最新PE估值-6.51，处于3年历史低位
机构加仓
最新机构持股81.01M股，环比增加0.03%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值927.54
活跃度增加
近期活跃度增加，过去20天平均换手率0.79
分析师目标
根据
7
位分析师
买入
评级
11.429
目标均价
+672.20%
涨幅空间
Ocugen Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ocugen Inc简介
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
公司代码OCGN
公司Ocugen Inc
CEOMusunuri (Shankar)
网址https://ocugen.com/
相关品种
热门品种
常见问题
Ocugen Inc(OCGN)的当前股价是多少？
Ocugen Inc(OCGN)的当前股价是 1.51。
Ocugen Inc的股票代码是什么？
Ocugen Inc的股票代码是OCGN。
Ocugen Inc股票的52周最高点是多少？
Ocugen Inc股票的52周最高点是2.73。
Ocugen Inc股票的52周最低点是多少？
Ocugen Inc股票的52周最低点是0.80。
Ocugen Inc的市值是多少？
Ocugen Inc的市值是510.86M。
现在Ocugen Inc(OCGN)的股票是买入、持有还是卖出？
根据分析师评级，Ocugen Inc(OCGN)的总体评级为买入，目标价格为11.43。
Ocugen Inc(OCGN)股票的每股收益（EPS TTM）是多少
Ocugen Inc(OCGN)股票的每股收益（EPS TTM）是-0.23。